In this study in silico docking models were employed to investigate the molecular interactions between the receptor-binding domain (RBD) of the SARS-CoV-2 spike glycoprotein, derived from the ...

Drug discovery requires two separate steps: checking whether a drug can bind to a harmful molecule or its receptor, and finding out if the drug can stop the molecule and its receptor from interacting.

SARS-CoV-2, the virus responsible for COVID-19, infects cells by binding its spike protein to angiotensin-converting enzyme 2 (ACE2) receptors. Blocking this interaction with inhibitors could prevent ...

Monoclonal antibodies (mAbs) are vital for preventing and treating COVID-19 by targeting the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein. However, the rapid emergence of Omicron ...

In a recent research paper uploaded to the bioRxiv preprint* server, researchers developed and tested novel bispecific antibodies (bsAbs) comprising both the N-terminal domain (NTD) and the receptor ...

As scientists, we often think we understand a virus—its structure, its tricks, the way it moves through the body. But every once in a while, we stumble upon something unexpected—something that ...

In a recent article published in Cell Reports, researchers from China investigated the immunodominant antibody responses induced by mosaic Receptor-binding domain (RBD) nanoparticles derived from ...